The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level

scientific article published on April 1987

The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.7326/0003-4819-106-4-524
P698PubMed publication ID3103510

P50authorMichelle A. PetriQ67485110
P2093author name stringCorash L
Hellmann D
Whiting-O'Keefe Q
Rheinschmidt M
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectsystemic lupus erythematosusQ1485
antibodyQ79460
anticoagulantQ215118
patientQ181600
anticoagulationQ63279445
partial thromboplastin timeQ1755136
venomQ3386847
P304page(s)524-531
P577publication date1987-04-01
P1433published inAnnals of Internal MedicineQ564416
P1476titleThe frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level
P478volume106

Reverse relations

cites work (P2860)
Q371312832013 update: Hopkins lupus cohort
Q33487561A family study of anticardiolipin antibodies and associated clinical conditions
Q93515633Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases
Q33416443Anti-phospholipid antibody with recurrent venous thromboembolism and severe autoimmune thrombocytopenia
Q33423945Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations
Q59413161Anticorps antiphospholipides au cours du syndrome HELLP : étude clinique et biologique à partir de 68 patientes
Q34061131Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus
Q94940476Antiphospholipid Syndrome
Q33416855Antiphospholipid antibodies and recurrent pregnancy loss
Q73086663Antiphospholipid antibodies and the antiphospholipid antibody syndrome
Q33498510Antiphospholipid antibodies in pediatric lupus nephritis
Q37063656Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE.
Q85206714Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus
Q40893344Autoimmunity in depression: increased antiphospholipid autoantibodies
Q35189299Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report
Q33562091Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus
Q36734776Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
Q42208790Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis
Q33448275Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus
Q33447381Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients
Q35181703Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease
Q33915430Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort
Q31166031Diagnosis and pathogenesis of CNS lupus
Q45191182Diagnosis of the antiphospholipid syndrome in anticoagulated patients
Q34675389Evaluation and treatment of vasculitis in the critically ill patient
Q68098882False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abort
Q44460505Glomerulonephritis in a patient with anticardiolipin antibody
Q37161550High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus
Q73683618Hopkins Lupus Cohort. 1999 update
Q33379907Immunology and Clinical Importance of Antiphospholipid Antibodies
Q35632379Incidence of anticardiolipin antibodies and lupus anticoagulant factor among women experiencing unexplained recurrent abortion and intrauterine fetal death
Q47796229Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients
Q40834203Inflammatory ulcers
Q37823869Influence of the lupus anticoagulant on clotting tests
Q33392824Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients
Q61943926LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES
Q40603707Laboratory assessment of circulating anticoagulants.
Q33427841Laboratory evaluation of a bleeding patient
Q33502380Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset
Q67471070Lupus anticoagulant antibodies inhibit collagen-induced adhesion and aggregation of human plateletsin vitro
Q33393751Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations
Q36373318Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort
Q33492652Lupus-type "anticoagulant" in a dog with hemolysis and thrombosis
Q37111561Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus
Q35535848Obstetrical implications of antiphospholipid antibodies
Q33561285Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset
Q33498327Pathogenesis and treatment of the antiphospholipid antibody syndrome
Q28186234Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein
Q51578946Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.
Q33376853Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study
Q57316999Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection
Q33350168Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus
Q72355315Prevalence of antiphospholipid antibodies in nephropathies not due to systemic lupus erythematosus
Q86527461Prevention of recurrent stroke in patients with systemic lupus erythematosus or lupus anticoagulant
Q40815362Primary antiphospholipid antibody syndrome and cerebral ischemia: report on acute intervention in two cases and literature review with emphasis on therapeutic options
Q38325716Pulmonary hypertension in antiphospholipid syndrome
Q38075430Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis
Q51859166Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome.
Q41413515Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus.
Q33567589Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis
Q36709328Semiquantified noncalcified coronary plaque in systemic lupus erythematosus
Q33373583Significance of anti-phospholipid antibodies in patients with lupus nephritis
Q33494866Splenic infarction associated with anticardiolipin antibodies in a patient with acquired immunodeficiency syndrome
Q38844621Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment
Q33559469Superior mesenteric artery thrombosis associated with antiphospholipid syndrome.
Q38028943Systemic lupus erythematosus and the maternal-fetal dyad
Q46443879Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients
Q28344247Systemic lupus erythematosus presenting earlier as retinal vaso-occlusion
Q58004012Testing strategies for diagnosing lupus anticoagulant: Decision analysis
Q33393937The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.
Q35167259The Hopkins Lupus Pregnancy Center: 1987–1991 Update
Q34519511The lung in the antiphospholipid syndrome
Q67918343The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation
Q35656148The pulmonary physician and critical care. 5. Management of pulmonary embolism
Q49137186The testosterone hypothesis: Assessment since Geschwind and Behan, 1982.
Q33371184The ‘Primary’ Antiphospholipid Syndrome: Antiphospholipid Antibody Pattern and Clinical Features of a Series of 23 Patients
Q41475203Thrombotic syndromes and autoimmune diseases
Q38149851Transient ischemic attack and stroke in systemic lupus erythematosus
Q36709341Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus
Q44583525Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy).
Q48619504Visual scotomata resulting from lupus anticoagulant in a patient with lymphoma in remission
Q68013021Visual scotomata resulting from lupus anticoagulant in a patient with lymphoma in remission
Q67823941[Pleuropulmonary manifestations of systemic lupus erythematosus]
Q77541312[The lung in antiphospholipid syndrome]

Search more.